Deep Apple Therapeutics Inc., a portfolio company created and incubated by Apple Tree Partners, has raised $52 million in series A round.

Biopharmas raising money in public or private financings, including: Amazentis, Cadenza, Ocular, Vandria, Veru.

Carthera SA received an additional €4.5 million (US$4.9 million) from investors to take its series B funding round to €42 million despite a tough fundraising environment for med-tech companies. Frédéric Sottilini, CEO of Carthera, told BioWorld that the strong investor interest was testament to their confidence in the company’s Sonocloud technology for brain disorder treatment.

Vandria SA has announced a series A financing round raising $20.6 million (CHF18 million) to help advance its pipeline of first-in-class small-molecule mitophagy inducers.

Biopharmas raising money in public or private financings, including: Algernon, Encellin, Evolveimmune, Mitorx, Tome.

Med-tech firms raising money in public or private financings, including: BCV, Calyxo, Molecular Loop, Ondine.

Japan-California startup Shinobi Therapeutics Inc. has emerged from stealth mode with a $51 million series A round to advance its first off-the-shelf induced pluripotent stem cell (iPS)-T cell therapy against glypigan-3 (GPC3)-positive cancers toward the clinic.